pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PATH · news · pharmadog
← back to PATH
News mentioning PATH
310
stories
12d
Immunovant ends cutaneous lupus program after phase 2 flop
fiercebiotech
12d
Opinion: Mentally ill women deserve more support to have children
stat
12d
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
fiercebiotech
12d
Opinion: Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA
stat
12d
Compass vows to press on with FDA application despite new trial request
biospace
13d
Novartis secures new radioligand in $900M deal as competition strengthens
fiercebiotech
13d
Convergence: Global acceptance of NAMs concerns sponsors who want to use them
raps
14d
FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing
fda press
14d
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
biopharma dive
14d
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
fiercebiotech
14d
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
14d
Beyond Random Integration: Transposase cell line development shortening timeline & boosting titers
biospace
15d
Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy
fiercebiotech
17d
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
biopharma dive
17d
Lisata deal propels Marea’s drug pipeline to Wall Street
biopharma dive
18d
A Parkinson's biotech debut, fundraising campaign and licensing deal
endpoints
18d
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
endpoints
18d
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
biospace
18d
Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial
biospace
18d
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
18d
Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’
fiercebiotech
19d
Why a US senator wants a biotech leader in the White House who ‘has the president’s ear’
fiercebiotech
19d
For many, the retirement goal posts are shifting
biospace
20d
Rocket's Danon plans; Novo leaves Ascendis; Lilly's latest deal
endpoints
20d
FDA opens Operation TrialBlazer for applications, hoping to reshore early trials
biospace
20d
FDA launches pilot program to speed up early US drug research
biopharma dive
20d
FDA Launches Expedited IND Pilot, Begins Accepting Applications
fda press
20d
Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
fiercebiotech
20d
Blood centers can help biopharma scale cell and gene therapies
biospace
21d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
← prev
page 2 of 11
next →
